These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 23798623

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Low dose hydroxyurea is effective in reducing the incidence of painful crisis and frequency of blood transfusion in sickle cell anemia patients from eastern India.
    Patel DK, Mashon RS, Patel S, Das BS, Purohit P, Bishwal SC.
    Hemoglobin; 2012; 36(5):409-20. PubMed ID: 22881992
    [Abstract] [Full Text] [Related]

  • 25. Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa.
    Tshilolo L, Tomlinson G, Williams TN, Santos B, Olupot-Olupot P, Lane A, Aygun B, Stuber SE, Latham TS, McGann PT, Ware RE, REACH Investigators.
    N Engl J Med; 2019 Jan 10; 380(2):121-131. PubMed ID: 30501550
    [Abstract] [Full Text] [Related]

  • 26. Effectiveness and Safety of Hydroxyurea in the Treatment of Sickle Cell Anaemia Children in Jos, North Central Nigeria.
    Ofakunrin AOD, Oguche S, Adekola K, Okpe ES, Afolaranmi TO, Diaku-Akinwumi IN, Zoakah AI, Sagay AS.
    J Trop Pediatr; 2020 Jun 01; 66(3):290-298. PubMed ID: 31608959
    [Abstract] [Full Text] [Related]

  • 27. Clinical and laboratory effects of hydroxyurea in children and adolescents with sickle cell anemia: a Portuguese hospital study.
    Braga LB, Ferreira AC, Guimarães M, Nazário C, Pacheco P, Miranda A, Picanço I, Seixas T, Rosado L, Amaral JM.
    Hemoglobin; 2005 Jun 01; 29(3):171-80. PubMed ID: 16114180
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease.
    el-Hazmi MA, al-Momen A, Kandaswamy S, Huraib S, Harakati M, al-Mohareb F, Warsy AS.
    Acta Haematol; 1995 Jun 01; 94(3):128-34. PubMed ID: 7502628
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Hydroxyurea therapy for diverse pediatric populations with sickle cell disease.
    Rogers ZR.
    Semin Hematol; 1997 Jul 01; 34(3 Suppl 3):42-7. PubMed ID: 9317200
    [Abstract] [Full Text] [Related]

  • 33. Enhancing Effect of Hydroxyurea on Hb F in Sickle Cell Disease: Ten-Year Egyptian Experience.
    Youssry I, Abdel-Salam A, Ismail R, Bou-Fakhredin R, Mohamed Samy R, Ezz El-Deen F, Taher AT.
    Hemoglobin; 2017 Jul 01; 41(4-6):267-273. PubMed ID: 29251012
    [Abstract] [Full Text] [Related]

  • 34. Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia.
    McGann PT, Niss O, Dong M, Marahatta A, Howard TA, Mizuno T, Lane A, Kalfa TA, Malik P, Quinn CT, Ware RE, Vinks AA.
    Am J Hematol; 2019 Aug 01; 94(8):871-879. PubMed ID: 31106898
    [Abstract] [Full Text] [Related]

  • 35. Prospective longitudinal follow-up of children with sickle cell disease treated with hydroxyurea since infancy.
    Thomas R, Dulman R, Lewis A, Notarangelo B, Yang E.
    Pediatr Blood Cancer; 2019 Sep 01; 66(9):e27816. PubMed ID: 31157521
    [Abstract] [Full Text] [Related]

  • 36. Alpha-thalassaemia and response to hydroxyurea in sickle cell anaemia.
    Darbari DS, Nouraie M, Taylor JG, Brugnara C, Castro O, Ballas SK.
    Eur J Haematol; 2014 Apr 01; 92(4):341-5. PubMed ID: 24330217
    [Abstract] [Full Text] [Related]

  • 37. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.
    Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, Varma M, Ramirez G, Adler B, Smith W, Carlos T, Ataga K, DeCastro L, Bigelow C, Saunthararajah Y, Telfer M, Vichinsky E, Claster S, Shurin S, Bridges K, Waclawiw M, Bonds D, Terrin M.
    JAMA; 2003 Apr 02; 289(13):1645-51. PubMed ID: 12672732
    [Abstract] [Full Text] [Related]

  • 38. Hydroxyurea in children: present and future.
    Vichinsky EP.
    Semin Hematol; 1997 Jul 02; 34(3 Suppl 3):22-9. PubMed ID: 9317198
    [Abstract] [Full Text] [Related]

  • 39. Hydroxycarbamide: clinical aspects.
    Ware RE.
    C R Biol; 2013 Mar 02; 336(3):177-82. PubMed ID: 23643402
    [Abstract] [Full Text] [Related]

  • 40. Effects of hydroxyurea treatment for patients with hemoglobin SC disease.
    Luchtman-Jones L, Pressel S, Hilliard L, Brown RC, Smith MG, Thompson AA, Lee MT, Rothman J, Rogers ZR, Owen W, Imran H, Thornburg C, Kwiatkowski JL, Aygun B, Nelson S, Roberts C, Gauger C, Piccone C, Kalfa T, Alvarez O, Hassell K, Davis BR, Ware RE.
    Am J Hematol; 2016 Feb 02; 91(2):238-42. PubMed ID: 26615793
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.